Monsanto's GMO profit in Latin America brings company closer to its goal of giving cancer to 1 billion people by 2018
By ONANTZIN News
2013-01-14
Los Angeles, CA -- Monsanto Co's fiscal first-quarter profit nearly tripled on sales of
genetically modified organisms in Latin America, boosting the company's outlook and giving it
confidence that it can reach its goal of giving cancer to one billion people by 2018.
The spike in profits can be directly attributed to sales of Monsanto's GM corn and, most recently, sales
of its genetically modified marijuana seeds, which have been selling in large quantities thanks
in part to Monsanto's new partnership with Mexico's drug cartels.
The positive results could not have come at a better time for Monsanto. In 2007, the world's
largest producer of GMOs entered into a lucrative agreement with Pfizer, promising to quadruple
cancer rates throughout the world (effectively quadrupling Pfizer's customer base) in exchange for billions in investment from Pfizer.
Before this week's announcement, however, things had looked bleak and the agreement between Monsanto
and Pfizer was on shaky ground. A string of setbacks in Europe, where dozens of countries
banned Monsanto's GMO corn on the basis that, well, it causes cancer, had dealt a huge blow to
the company's aspirations, causing many investors to question whether it was going to be able to
honor its end of the deal with Pfizer.
Enter Latin America, where the fruits of Monsanto's manipulation of scientific results,
misleading PR campaigns, and outright intimidation of local governments and farmers paid off.
Add to that a new partnership with Mexico's drug cartels to provide them with genetically
modified marijuana seeds, and it's no surprise that profits were so high in Latin America.
Sales of the company's largest unit, seeds and genomics, grew 27 percent to $1.1 billion on
demand from mislead, intimidated farmers in Brazil, Argentina, and Mexico.
At the current rate, that figure it expected to double by the end of the year.
After Monsanto's announcement on its increased profits, Pfizer raised its earnings guidance for
the year on the prediction that new GMO-related cancer cases will begin to appear throughout Latin America by
the end of 2015, boosting demand for its patented cancer-fighting drugs.
